AstraZeneca advances ambition to improve standards of care in multiple cancer types at ...
The article presents various studies on antibody drug conjugates, including datopotamab deruxtecan (Dato-DXd) and trastuzumab deruxtecan (T-DXd), in different cancer types such as endometrial, ovarian, breast, lung, and gastric cancers. It also covers studies on immuno-oncology treatments like durvalumab and neoadjuvant strategies, as well as initial results from first-in-human studies of new antibody-drug conjugates like AZD8205 and AZD5335. Additionally, it discusses the role of circulating tumor DNA (ctDNA) dynamics in treatment responses and long-term survival outcomes in various cancer settings.
Reference News
Antibody-drug conjugates (ADCs) are emerging in oncology, with dozens approved by the FDA. ADCs offer a 'bystander effect' but can increase off-target toxicity. Aditya Bardia highlighted ADCs like sacituzumab govitecan, trastuzumab deruxtecan, and datopotamab deruxtecan, which show superiority over chemotherapy in metastatic settings. Domenica Lorusso noted over 260 ADCs in cancer trials, calling them a 'rising star' in ovarian cancer. Toon Van Gorp emphasized TROP2 as a key target in cervical cancer. Challenges include understanding ADC resistance mechanisms and managing toxicities, necessitating multidisciplinary approaches.
The article presents various studies on antibody drug conjugates, including datopotamab deruxtecan (Dato-DXd) and trastuzumab deruxtecan (T-DXd), in different cancer types such as endometrial, ovarian, breast, lung, and gastric cancers. It also covers studies on immuno-oncology treatments like durvalumab and neoadjuvant strategies, as well as initial results from first-in-human studies of new antibody-drug conjugates like AZD8205 and AZD5335. Additionally, it discusses the role of circulating tumor DNA (ctDNA) dynamics in treatment responses and long-term survival outcomes in various cancer settings.